Prof. Laurie H. Glimcher from Sandra and Edward Meyer Cancer Center of Weill Cornell Medical College, New York; Prof Matthew B. Greenblatt from Department of Pathology, Brigham and Women’s Hospital, Harvard medical school, Boston, Massachusetts, USA; and others had reported in the prestigious journal Nature (508, 103–107 (03 April 2014) that: “XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway”
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: MiRNA-based treatment for triple-negative breast cancer: miR-30c-2-3p inhibits triple-negative breast cancer via down regulation of its target gene.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based treatment for triple-negative breast cancer: miR-30c-2-3p inhibits triple-negative breast cancer via down regulation of its target gene, 19/April/2014, 6.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
